An experimental pill from Merck was shown in a trial to cut the risk of COVID-19 hospitalization and death in half, the company has announced.
The drugmaker said Friday that in a trial, those who received its pill to treat COVID-19, molnupiravir, within five days of experiencing symptoms had half the rate of hospitalization and death as patients who received a placebo, The Associated Press reports. According to Merck, the rate of hospitalizations or deaths was 7.3 percent among those patients who received molnupiravir compared to 14.1 percent for the placebo group.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Europe records big leap in renewable energySpeed Read Solar power overtook coal for the first time
-
Blue Origin conducts 1st test flight of massive rocketSpeed Read The Jeff Bezos-founded space company conducted a mostly successful test flight of its 320-foot-tall New Glenn rocket
-
US won its war on 'murder hornets,' officials saySpeed Read The announcement comes five years after the hornets were first spotted in the US
-
Dark energy data suggest Einstein was rightSpeed Read Albert Einstein's 1915 theory of general relativity has been proven correct, according to data collected by the Dark Energy Spectroscopic Instrument
-
New DNA tests of Pompeii dead upend popular storiesSpeed Read An analysis of skeletal remains reveals that some Mount Vesuvius victims have been wrongly identified
-
NASA's Europa Clipper blasts off, seeking an oceanSpeed Read The ship is headed toward Jupiter on a yearslong journey
-
Detailed map of fly's brain holds clues to human mindSpeed Read This remarkable fruit fly brain analysis will aid in future human brain research
-
What does Covid look like in 2024?Today's Big Question Disease experts are calling for closer monitoring as new variant fuels rise in infections
